Monte Rosa Therapeutics Reports Third-Quarter 2026 Results and Business Updates
The company said positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic disease.
Related stories
Papa John's Reports Q3 EPS In Line, Revenue Misses
Papa John's reported Q3 earnings of $0.16 per share, excluding non-recurring items, in line with FactSet estimates. Revenue missed estimates.
M impact | EQUITY | Nov 05, 2026, 12:14 PM UTC
Marex Group reports Q3 earnings of $1.67 per share
Marex Group reported Q3 earnings of $1.67 per share, excluding non-recurring items, $0.13 above expectations. The headline also says revenue beat expectations.
M impact | EQUITY | Nov 05, 2026, 12:13 PM UTC
Wendy’s Q3 Adjusted EPS Tops Estimate, Revenue Falls Short
Wendy’s reported adjusted EPS of USD 0.13 versus an IBES estimate of USD 0.09. Q3 adjusted revenue was USD 435.6 million versus an IBES estimate of USD 530.5 million.
M impact | EQUITY | Nov 05, 2026, 12:09 PM UTC
DNOW Q3 Profit Beats Estimates on Growth Across Segments
M impact | EQUITY | Nov 05, 2026, 12:09 PM UTC
Malibu Boats reports Q1 net loss
Malibu Boats reported Q1 net income of USD -6.1 million; Reuters also reported gross profit of USD 37.8 million.
M impact | EQUITY | Nov 05, 2026, 12:09 PM UTC
Amylyx Pharmaceuticals Reports $45.5M Third-Quarter Loss
M impact | EQUITY | Nov 05, 2026, 12:09 PM UTC